Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Dermira Inc
DERM | US
4.64
USD-0.05
-1.07%
DERM | US
Loading StockChartView...
About Dermira Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
01/04/2026
Close
4.64
Open
4.71
High
5.00
Low
4.61
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane an oral isotretinoin drug to treat severe recalcitrant acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi a topical minocycline treatment for inflammatory lesions; Ximino an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets minocycline hydrocholoride capsules and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech Inc.
View LessDERM | US
Risk
110.9
Sharpe
-0.38
Luna's Score
24/100
Recommendation
Sell
Luna says (DERM | US)
What's Working
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
150.3%1 month
110.9%3 months
81.2%6 months
68.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
47.08
Fwd. PE
17.21
Price to book
11.52
Debt to equity
2.02
Debt to assets
0.35
Ent. to EBITDA
21.68
Ent. to rev.
1.62
PEG
-
Other Fundamentals
EBITDA
5.38M
MarketCap
96.17M
MarketCap(USD)
96.17M
Div. yield
-
Op. margin
-19.70
Erngs. growth
-
Rev. growth
-13.50
Ret. on equity
14.92
Short ratio
2.10
Short perc.
2.03
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.38
Range1M
4.18
Range3M
5.25
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.90
Price X volume
1.26M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 21.68 | 0.53 | Expensive |
| Ent. to Revenue | 1.62 | 3,967.00 | Cheaper |
| PE Ratio | 47.08 | 41.03 | Par |
| Price to Book | 11.52 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 81.18 | 72.80 | Par |
| Debt to Equity | 2.02 | -1.23 | Expensive |
| Debt to Assets | 0.35 | 0.25 | Expensive |
| Market Cap | 96.17M | 3.66B | Emerging |
